Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 5/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | APP | P05067 | 3/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2940477 | 0.85 | CTSL (0.57) | CTSLCTSBCTSKNAAAHRH3 | |
| SCHEMBL17274394 | 0.84 | CARM1 (0.44) | CTSLCTSBCTSKRXRARXRB | |
| SCHEMBL16422780 | 0.84 | NAAA (0.54) | CTSLCTSBCTSKNAAA | |
| SCHEMBL21618373 | 0.84 | NAAA (0.54) | CTSLCTSBCTSKNAAAHRH3 | |
| SCHEMBL25257331 | 0.82 | NAAA (0.44) | CTSLCTSBCTSKNAAAIDO1 | |
| SCHEMBL13519043 | 0.81 | CTSL (0.42) | CTSLCTSBCTSKNAAA | |
| SCHEMBL25295010 | 0.80 | PRMT5 (0.44) | — | |
| SCHEMBL18764160 | 0.79 | NAAA (0.62) | NAAA | |
| SCHEMBL27144034 | 0.79 | CARM1 (0.49) | NAAAHRH3 | |
| SCHEMBL25295332 | 0.77 | PTPRZ1 (0.46) | CTSLCTSBCTSKRXRANAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | CTSL 1320/4885CTSB 899/4885CTSK 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.